RECRUITING

Probing the Dorsolateral Prefrontal Cortex and Central Executive Network for Improving Neuromodulation in Depression

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Depression is a highly prevalent condition characterized by persistent low mood, energy, and activity that can affect one's thoughts, mood, behavior, and sense of well-being. Repetitive transcranial magnetic stimulation (rTMS), a non-invasive neuromodulatory technique, is an effective treatment for depression when targeting the dorsolateral prefrontal cortex (dlPFC) of the central executive network (CEN). However, remission rates are suboptimal and individual methods to target the dlPFC are lacking. In this study, we will enroll 50 patients with major depression and in a single rTMS 'dose,' prospective, randomized, double-blind, cross-over design will assess whether rTMS targeted to an individual's central executive network (CEN) assessed by single pulse TMS can enhance network modulation. If successful, this work will lead to a clinical rTMS trial comparing this personalized targeting approach against standard rTMS.

Official Title

CRCNS US-France Research Proposal: Probing the Dorsolateral Prefrontal Cortex and Central Executive Network for Improving Neuromodulation in Depression

Quick Facts

Study Start:2023-01-01
Study Completion:2025-06-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05224063

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 65 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Men and women, ages 18 to 65
  2. * Depression assessed through in-depth Structured Clinical Interview for DMS-5 (SCID-I)
  3. * PHQ9 \> 10 for disease severity
  4. * Must comprehend English well to ensure adequate comprehension of the EEG and TMS instructions, and of clinical scales
  5. * Right-handed
  6. * No current or history of neurological disorders
  7. * No seizure disorder or risk of seizures
  8. * No use of PRN medication within 24 hours of the scheduled study appointment
  1. * Those with a contraindication for MRIs (e.g. implanted metal)
  2. * Any unstable medical condition
  3. * History of head trauma with loss of consciousness
  4. * History of seizures
  5. * Neurological or uncontrolled medical disease
  6. * Active substance abuse
  7. * Diagnosis of psychotic or bipolar disorder
  8. * A prior history of ECT or rTMS failure
  9. * Currently taking medications that substantially reduce seizure threshold (e.g., olanzapine, chlorpromazine, lithium)
  10. * Currently pregnant or breastfeeding

Contacts and Locations

Study Contact

Corey Keller, MD, PhD
CONTACT
(650) 498-9111
kellerlab@stanford.edu

Study Locations (Sites)

Stanford University
Stanford, California, 94305
United States

Collaborators and Investigators

Sponsor: Stanford University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-01-01
Study Completion Date2025-06-30

Study Record Updates

Study Start Date2023-01-01
Study Completion Date2025-06-30

Terms related to this study

Additional Relevant MeSH Terms

  • Major Depressive Disorder